Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis.
Prevention of decompensation is a primary therapeutic target in patients with compensated cirrhosis. However, a major problem is the large sample size and long follow-up required to demonstrate a significant treatment effect because of the relatively low baseline risk. For this reason, it has been recently suggested that ordinal outcomes may be used in this area to gain power and to reduce sample size. The aim of this study was to assess the applicability of ordinal outcomes in cirrhosis. An inception cohort of 202 patients with compensated cirrhosis (no ascites, gastrointestinal bleeding, encephalopathy, or jaundice) without esophageal varices was included, and 5-year outcome is reported. Etiology was mostly viral and alcoholic, and there were no dropouts. The ordinal outcome was set according to six grades with a previously established prognostic ordinality: grade 1=no disease progression; grade 2=development of varices; grade 3 = bleeding alone; grade 4=nonbleeding single decompensation; grade 5=more than one decompensating event; and grade 6=death. At the 60-month time point, patients were distributed in grades 1 through 6 as follows: 129, 43, 2, 7, 5, and 16, respectively. Emulation of a clinical trial performed by dividing patients based on baseline platelet count into two groups (cutoff 150×109 /L) demonstrated a statistically significant outcome difference between groups when using ordinal outcomes not detectable by binary logistic or chi-square or time-to-event analyses. Additionally, using ordinal outcomes in a hypothetical study to prevent decompensation resulted in sample size estimates 3-to 4-fold lower than using a binary composite endpoint. Conclusion: Compared to traditional binary outcomes, the use of ordinal outcomes in trials of cirrhosis decompensation may provide more power and thus may require a smaller sample size.